Get Smarter on Biotech in 5 Minutes a Day.
Focused insights — expertly curated, clearly delivered, ready for action.
Get the Daily Brief
What’s in Today’s Brief? (November 18th Preview)
-
Regulatory and policy shakeups at FDA and MHRA
The White House withdrew Heidi Overton’s nomination to lead the U.S. Food and Drug Administration, adding uncertainty to an agency already operating without a confirmed permanent commissioner. Analysts said the change is unlikely to immediately disrupt day-to-day operations, but it heightens scrutiny over who will set priorities for drug review policy, user fee reauthorization, and the FDA’s approach to emerging tools in science. In the UK, the Medicines and Healthcare products Regulatory Agency (MHRA) announced it will begin accepting certain trial applications that rely on non-OECD preclinical safety data for serious diseases where patients lack other treatment options. OECD-generated data remains the preferred standard overall, while MHRA plans risk-based inspections of frequently used non-OECD test facilities. Taken together, the two developments point to a near-term governance and evidence-access reset—one focused on leadership continuity at the FDA and another on regulatory flexibility for globalized nonclinical data packages in early-stage development.
-
Big pharma doubles down on in vivo CAR-T
Pfizer expanded its immunology pipeline into in vivo CAR-T through a licensing deal with Starna Therapeutics. The company secured global rights outside Greater China to three preclinical in vivo CAR-T programs targeting undisclosed autoimmune diseases, as well as the ability to use Starna’s in-body reprogramming technology across inflammation, immunology and oncology. Under the terms reported for the transaction, Pfizer will pay Starna $330 million upfront, with additional milestone payments that could reach $2.3 billion. The deal also includes royalties on any approved products. This adds momentum to the shift toward faster, potentially less resource-intensive cell therapies that avoid ex vivo manufacturing complexity—an area seeing multiple large-company transactions in recent years.
-
Clinical durability update in FLT3-mutated AML
Long-term follow-up presented at the 2025 ASH Annual Meeting showed gilteritinib in combination with venetoclax and azacitidine delivered a median overall survival of 29.7 months in newly diagnosed FLT3-mutated acute myeloid leukemia. The update reinforces the durability signal for a triplet approach in a high-risk genomic subset. The report focuses on extended outcomes rather than short-term response measures, giving trial stakeholders more data to compare against other front-line FLT3 strategies. The results are tied to the specific regimen of gilteritinib plus venetoclax and azacitidine rather than gilteritinib monotherapy. For clinicians and payers, the key actionability is the magnitude and persistence of survival outcomes in a space where OS duration is often the deciding metric for treatment adoption.
-
Dual-target CAR T advances in high-risk extramedullary myeloma
A phase 1/2 study reported durable activity for a dual-targeting BCMA and CD19 CAR T program in heavily pretreated relapsed or refractory multiple myeloma, including patients with extramedullary disease. The study described deep hematologic and metabolic responses, highlighting a potential pathway for difficult disease biology beyond bone marrow involvement. Because extramedullary myeloma is associated with poor outcomes with standard approaches, the trial’s inclusion of those patients makes the durability signal more clinically meaningful. The update frames the program as showing sustained responses rather than only transient remission. For CAR T developers, the headline takeaway is the feasibility of dual antigen targeting to maintain response pressure in high-risk disease compartments.
-
Ocular anti-angiogenesis via rapamycin nanoparticle delivery
Polymer nanoparticles delivering sustained-release rapamycin showed strong suppression of ocular blood-vessel growth in animal models of wet age-related macular degeneration. The platform used a chitosan-coated nanoparticle formulation and reduced pathological vessel formation while also decreasing inflammation and retinal damage. The study is framed as preclinical evidence for a long-acting approach that targets angiogenesis and the downstream tissue injury cascade, rather than only measuring vascular endpoints. It also emphasizes sustained release—an important design parameter for chronic retinal disorders. While the work remains in animals, it provides a mechanistic and translational candidate for developers seeking non-invasive dosing strategies for retinal neovascular disease.
...and 5 more selected Biotech stories in today’s full edition — or archive.
Why BioBriefs?
- Expertly curated. We scan 200+ sources daily to deliver only what matters.
- Smart context. Each brief explains why it matters and who it impacts.
- Made for pros. Trusted by founders, scientists, investors, and strategists.
Who Reads BioBriefs?
- Biotech founders & execs
- R&D and Clinical leads
- Life sciences investors
- Regulators and BD pros
- Translational scientists and tech scouts
Stay sharp. Be first to what’s next.
About BioBriefs
We’re a team of biotech analysts, technical writers, and founders who know what it’s like to scan 40 tabs and still miss what matters. BioBriefs was built to solve that. We track the signals, condense the insights, and get them to you before your day starts.